Objective: To analyze the clinical distribution and infection characteristics of clinical isolates of non-Acinetobacter baumannii(non-A. baumannii). Methods: A total of 197 non-A. baumannii strains isolated from January 2021 to June 2023 at the Fourth Affiliated Hospital of Soochow University were collected. The strains were classified into A. nosocomialis, A. pittii/seifertii, and non-A. calcoaceticus-baumannii (ACB) complex, and their clinical distributions and infection characteristics were compared. Results: The isolation rate of non-A. baumannii had been increasing annually. There was no statistically significant difference in the drug resistance rates of the different non-A. baumannii strains to 15 types of drugs. The mean age of patients infected with non-ACB complex was the highest[(69.68±14.65) years]. For A. nosocomialis infections, the average hospital stay was the longest [(30.81±18.54) d], the ICU admission rate(31.25%) and the proportion of adverse outcomes(9.38%) were all the highest among the three groups of non-A. baumannii infections. The differences in average hospital stay and ICU admission rates among the three types of non-A. baumannii infections were statistically significant(P<0.05). Non-A. baumannii infections were mostly hospital-acquired, and co-detection with other bacteria was common. Compared with patients with single bacterial detection, those with mixed bacterial detection had a higher proportion of male patients, a higher proportion of long hospital stays(≥28 d), a higher rate of invasive procedures, a higher rate of ICU stay history, increased white blood cell count, increased neutrophil ratio, and higher procalcitonin levels, with all differences being statistically significant(P<0.05). Conclusion: The detection of non-A. baumanni has been increasing yearly, and different non-A. baumannii strains exhibit different clinical distributions and infection characteristics. Therefore, increased attention and monitoring of non-A. baumannii infections in the hospital setting are warranted. |
[1] BRISOU J,PREVOT A R.Studies on bacterial taxonomy.X.The revision of species under Acromobacter group[J].Ann Inst Pasteur(Paris),1954,86(6):722-728.
[2] NEMEC A,MUSÍLEK M,ŠEDO O,et al.Acinetobacter bereziniae sp.nov.and Acinetobacter guillouiae sp.nov., to accommodate Acinetobacter genomic species 10 and 11, respectively[J].Int J Syst Evol Microbiol,2010,60(4):896-903.
[3] VANEECHOUTTE M,DE BAERE T,NEMEC A,et al.Reclassification of Acinetobacter grimontii Carr et al.2003 as a later synonym of Acinetobacter junii Bouvet and Grimont 1986[J].Int J Syst Evol Microbiol,2008,58(4):937-940.
[4] KITANAKA H,SASANO M A,YOKOYAMA S,et al.Invasive infection caused by carbapenem-resistant Acinetobacter soli, Japan[J].Emerg Infect Dis,2014,20(9):1574-1576.
[5] BONNIN R A,OCAMPO-SOSA A A,POIREL L,et al.Biochemical and genetic characterization of carbapenem-hydrolyzing β-lactamase OXA-229 from acinetobacter bereziniae[J].Antimicrob Agents Chemother,2012,56(7):3923-3927.
[6] CHUSRI S,CHONGSUVIVATWONG V,RIVERA J I,et al.Clinical outcomes of hospital-acquired infection with acinetobacter nosocomialis and acinetobacter pittii[J].Antimicrob Agents Chemother,2014,58(7):4172-4179.
[7] HIGGINS P G,JANBEN K,FRESEN M M,et al.Molecular epidemiology of acinetobacter baumannii bloodstream isolates obtained in the United States from 1995 to 2004 using rep-PCR and multilocus sequence typing[J].J Clin Microbiol,2012,50(11):3493-3500.
[8] LIU Y M,LEE Y T,KUO S C,et al.Comparison between bacteremia caused by Acinetobacter pittii and Acinetobacter nosocomialis[J].J Microbiol Immunol Infect,2017,50(1):62-67.
[9] DAVIS J S,MCMILLAN M,SWAMINATHAN A,et al.A 16-year prospective study of community-onset bacteremic acinetobacter pneumonia[J].Chest,2014,146(4):1038-1045.
[10] LAI H H,LIOU B H,CHANG Y Y,et al.Risk factors and clinical outcome ofsulbactam nonsusceptibility inmonomicrobial Acinetobacter nosocomialis bacteremia[J].J Microbiol Immunol Infect,2016,49(3):371-377.
[11] RUAN Z,CHEN Y,WANG J.Glimpse into the genome sequence of a multidrug-resistant Acinetobacter pittii ST950 clinical isolate carrying the blaOXA-72 and blaOXA-533 genes in China[J].Mem Inst Oswaldo Cruz,2017,112(10):723-727.
[12] D'SOUZA R,PINTO N A,HIGGINS P G,et al.First report of the carbapenemase gene blaOXA-499 in acinetobacter pittii[J].Antimicrob Agents Chemother,2017,61(5):e02616-e02676.
[13] LÁZARO-DÍEZ M,CHAPARTEGUI-GONZÁLEZ I,REDONDO-SALVO S,et al.Human neutrophils phagocytose and kill Acinetobacter baumannii and A.pittii[J].Sci Rep,2017,7:4571.
[14] PAILHORIōS H,TIRY C,EVEILLARD M,et al.Acinetobacter pittii isolated more frequently than Acinetobacter baumannii in blood cultures:the experience of a French hospital[J].J Hosp Infect,2018,99(3):360-363.
[15] LAI C C,HSU H L,TAN C K,et al.Recurrent bacteremia caused by the acinetobacter calcoaceticus-acinetobacter baumannii complex[J].J Clin Microbiol,2012,50(9):2982-2986.
[16] WU H S,KUO S C,LEE Y T,et al.Clinical characteristics and prognostic factors of Acinetobacter nosocomialis bacteraemia in patients with solid tumours[J].Clin Microbiol Infect,2012,18(9):E373-E376.
[17] TSAI H Y,CHENG A,LIU C Y,et al.Bacteremia caused by Acinetobacter junii at a medical center in Taiwan,2000-2010[J].Eur J Clin Microbiol Infect Dis,2012,31(10):2737-2743.
[18] 戢运超.2568株革兰阴性杆菌的感染情况及耐药性分析[J].现代医学,2014,42(3):312-314.
[19] 杜超.近3年枣阳市妇幼保健院鲍曼不动杆菌分布特点、耐药性分析及防治对策[J].现代医学,2013,41(10):758-760. |